<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> are characterized by the association of <z:mp ids='MP_0005048'>thrombosis</z:mp> or pregnancy morbidity and the presence of antiphospholipid autoantibodies </plain></SENT>
<SENT sid="1" pm="."><plain>Particularly, anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (beta(2) GPI) autoantibodies correlate with <z:mp ids='MP_0005048'>thrombosis</z:mp>, suggesting an antibody-induced gain of prothrombotic function and/or an antibody-induced loss of antithrombotic function of beta(2) GPI </plain></SENT>
<SENT sid="2" pm="."><plain>In the search for potential antithrombotic properties of beta(2) GPI, we found that beta(2) GPI inhibits <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (VWF)-induced platelet aggregation </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to a VWF-coated surface was decreased by 50% in the presence of beta(2) GPI (P &lt; .03) </plain></SENT>
<SENT sid="4" pm="."><plain>beta(2) GPI binds to the A1 domain of VWF but preferably when the A1 domain is in its active <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> Ibalpha-binding conformation </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-beta(2) GPI antibodies isolated from a subset of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> patients neutralized the beta(2) GPI-VWF interactions and thus the inhibitory activity of beta(2) GPI </plain></SENT>
<SENT sid="6" pm="."><plain>In comparison to healthy individuals, the amounts of active VWF in circulation were increased 1.5-fold (P &lt; .001) in patients positive for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) due to anti-beta(2) GPI antibodies </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, beta(2) GPI is a biologically relevant inhibitor of VWF function by interfering with VWF-dependent platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Anti-beta(2) GPI autoantibodies neutralize this inhibitory function and are associated with increased levels of active VWF </plain></SENT>
<SENT sid="9" pm="."><plain>This mode of action could contribute to the <z:mp ids='MP_0005048'>thrombosis</z:mp> and consumptive <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> observed in patients with anti-beta(2) GPI antibodies </plain></SENT>
</text></document>